SG11202008098TA - Antibody-based methods of detecting and treating alzheimer's disease - Google Patents
Antibody-based methods of detecting and treating alzheimer's diseaseInfo
- Publication number
- SG11202008098TA SG11202008098TA SG11202008098TA SG11202008098TA SG11202008098TA SG 11202008098T A SG11202008098T A SG 11202008098TA SG 11202008098T A SG11202008098T A SG 11202008098TA SG 11202008098T A SG11202008098T A SG 11202008098TA SG 11202008098T A SG11202008098T A SG 11202008098TA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- disease
- detecting
- based methods
- treating alzheimer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862649208P | 2018-03-28 | 2018-03-28 | |
| US201862664662P | 2018-04-30 | 2018-04-30 | |
| US201862703299P | 2018-07-25 | 2018-07-25 | |
| PCT/IB2019/000358 WO2019186276A2 (en) | 2018-03-28 | 2019-03-27 | Antibody-based methods of detecting and treating alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202008098TA true SG11202008098TA (en) | 2020-10-29 |
Family
ID=66999856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202008098TA SG11202008098TA (en) | 2018-03-28 | 2019-03-27 | Antibody-based methods of detecting and treating alzheimer's disease |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3774887A2 (en) |
| JP (1) | JP2021520777A (en) |
| KR (1) | KR20200144551A (en) |
| CN (1) | CN112236452A (en) |
| AU (1) | AU2019244481A1 (en) |
| BR (1) | BR112020018868A2 (en) |
| CA (1) | CA3095443A1 (en) |
| IL (1) | IL277577A (en) |
| MX (1) | MX2020009991A (en) |
| RU (1) | RU2020135052A (en) |
| SG (1) | SG11202008098TA (en) |
| WO (1) | WO2019186276A2 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201506244VA (en) | 2013-03-13 | 2015-09-29 | Prothena Biosciences Ltd | Tau immunotherapy |
| DK3452507T3 (en) | 2016-05-02 | 2022-11-14 | Prothena Biosciences Ltd | TAU IMMUNOTHERAPY |
| BR112018072389A2 (en) | 2016-05-02 | 2019-02-19 | Prothena Biosciences Limited | antibodies that recognize tau |
| SG11201910066QA (en) | 2017-05-02 | 2019-11-28 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| TW202100550A (en) | 2019-03-03 | 2021-01-01 | 愛爾蘭商普羅帝納生物科學公司 | Antibodies recognizing tau |
| CA3150156A1 (en) | 2019-09-09 | 2021-03-18 | Michal Novak | Biomarkers and treatments of alzheimer's disease and mild cognitive impairment |
| EP4263599A1 (en) * | 2020-12-16 | 2023-10-25 | Voyager Therapeutics, Inc. | Tau binding compounds |
| BR112023014151A2 (en) * | 2021-02-19 | 2023-10-10 | Eisai R&D Man Co Ltd | TAU ANTI-PT217 ANTIBODY |
| CN117003863A (en) * | 2022-04-28 | 2023-11-07 | 厦门大学 | Antibodies to p-tau 217 and uses thereof |
| CN114778856B (en) * | 2022-05-30 | 2023-03-17 | 苏州宇测生物科技有限公司 | Phosphorylated tau protein detection kit |
| WO2024040212A2 (en) * | 2022-08-19 | 2024-02-22 | Staidson Biopharma Inc. | Antibodies specifically recognizing programmed cell death 1 ligand 1 and uses thereof |
| CN117624351B (en) * | 2023-11-24 | 2024-07-05 | 无锡傲锐东源生物科技有限公司 | Anti-human phosphorylated tau181 rabbit monoclonal antibody and application thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| EP0652775B1 (en) | 1992-07-27 | 2000-04-19 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Targeting of liposomes to the blood-brain barrier |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| CU22615A1 (en) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | PROCEDURE FOR OBTAINING LESS IMMUNOGENIC MONOCLONAL ANTIBODIES. MONOCLONAL ANTIBODIES OBTAINED |
| PT1516628E (en) | 1995-07-27 | 2013-09-24 | Genentech Inc | Stable isotonic lyophilized protein formulation |
| WO1997023243A1 (en) | 1995-12-22 | 1997-07-03 | Bristol-Myers Squibb Company | Branched hydrazone linkers |
| WO1998022120A1 (en) * | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
| JP2002512624A (en) | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | Method for producing non-immunogenic protein |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
| DE10121982B4 (en) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanoparticles of protein with coupled apolipoprotein E to overcome the blood-brain barrier and process for their preparation |
| AU2003246664B2 (en) | 2002-07-12 | 2007-06-14 | Axon Neuroscience Se | Transgenic animal expressing Alzheimer's tau protein |
| KR101111477B1 (en) | 2002-12-03 | 2012-02-23 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | A conjugate comprising cholesterol linked to a therapeutic agent |
| MXPA05006940A (en) | 2002-12-24 | 2006-02-22 | Neurochem Int Ltd | Therapeutic formulations for the treatment of beta-amyloid related diseases. |
| SI1725249T1 (en) | 2003-11-06 | 2014-04-30 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| WO2006034488A2 (en) | 2004-09-23 | 2006-03-30 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| WO2008140639A2 (en) * | 2007-02-08 | 2008-11-20 | Oligomerix, Inc. | Biomarkers and assays for alzheimer's disease |
| US8093018B2 (en) * | 2008-05-20 | 2012-01-10 | Otsuka Pharmaceutical Co., Ltd. | Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same |
| US8613924B2 (en) * | 2009-08-06 | 2013-12-24 | Immunas Pharma, Inc. | Antibodies that specifically bind to A beta oligomers and use thereof |
| CN109265543B (en) | 2011-09-19 | 2022-04-26 | 阿克松神经系统科学公司 | Protein-based therapy and diagnosis of TAU protein-mediated pathologies in alzheimer's disease |
| SI2794654T1 (en) * | 2011-12-20 | 2019-08-30 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
| US8853505B2 (en) * | 2012-02-27 | 2014-10-07 | Syngenta Participations Ag | Variety corn line AA2205 |
| US8980270B2 (en) * | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| RU2730668C2 (en) | 2014-11-19 | 2020-08-24 | Аксон Ньюросайенс Се | Humanised tau antibodies in alzheimer disease |
| CN107531797B (en) * | 2016-02-05 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | Thrombin antibody, antigen binding fragment thereof and medical application |
-
2019
- 2019-03-27 BR BR112020018868-9A patent/BR112020018868A2/en unknown
- 2019-03-27 EP EP19732436.1A patent/EP3774887A2/en active Pending
- 2019-03-27 MX MX2020009991A patent/MX2020009991A/en unknown
- 2019-03-27 CA CA3095443A patent/CA3095443A1/en active Pending
- 2019-03-27 JP JP2020551506A patent/JP2021520777A/en active Pending
- 2019-03-27 RU RU2020135052A patent/RU2020135052A/en unknown
- 2019-03-27 KR KR1020207030584A patent/KR20200144551A/en unknown
- 2019-03-27 CN CN201980029711.2A patent/CN112236452A/en active Pending
- 2019-03-27 AU AU2019244481A patent/AU2019244481A1/en active Pending
- 2019-03-27 WO PCT/IB2019/000358 patent/WO2019186276A2/en unknown
- 2019-03-27 SG SG11202008098TA patent/SG11202008098TA/en unknown
-
2020
- 2020-09-24 IL IL277577A patent/IL277577A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3774887A2 (en) | 2021-02-17 |
| AU2019244481A1 (en) | 2020-10-01 |
| KR20200144551A (en) | 2020-12-29 |
| CA3095443A1 (en) | 2019-10-03 |
| WO2019186276A2 (en) | 2019-10-03 |
| JP2021520777A (en) | 2021-08-26 |
| IL277577A (en) | 2020-11-30 |
| RU2020135052A (en) | 2022-04-29 |
| WO2019186276A8 (en) | 2020-10-15 |
| BR112020018868A2 (en) | 2021-01-26 |
| CN112236452A (en) | 2021-01-15 |
| MX2020009991A (en) | 2020-10-14 |
| WO2019186276A3 (en) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277577A (en) | Antibody-based methods of detecting and treating alzheimer's disease | |
| IL254030B (en) | Use of pridopidine to improve cognitive function and for treating alzheimer's disease | |
| IL280315A (en) | Methods of treatment and prevention of alzheimer's disease | |
| IL263433A (en) | Methods for treating alzheimer's disease | |
| ZA201605341B (en) | Methods of treating alzheimer's disease | |
| SG11201606490YA (en) | Methods of treating alzheimer's disease | |
| SG11202011296VA (en) | Compositions and methods for the treatment of parkinson's disease | |
| EP3458036A4 (en) | Methods of treating or preventing alzheimer's disease and associated conditions | |
| EP3377118A4 (en) | Methods for treating alzheimer's disease and related disorders | |
| IL288894A (en) | Methods for evaluation and treatment of alzheimer's disease and applications thereof | |
| IL276896A (en) | Methods of treating crohn's disease with anti-il23 specific antibody | |
| EP3558340A4 (en) | Methods of using gm6 in diagnosing and treating alzheimer's disease | |
| MA45865A (en) | METHODS FOR DETECTION AND TREATMENT OF A TUMOR EXPRESSING PT346 PDK1 | |
| IL277182A (en) | Compositions and methods for treating parkinson's disease | |
| EP3347486A4 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
| IL281395A (en) | Use of low volume plasma exchange for treating the early and middle stages of alzheimer's disease | |
| ZA202101489B (en) | Compositions and methods for the treatment of parkinson's disease | |
| EP3490546A4 (en) | Methods of treating or preventing amyloid related imaging abnormalities associated with alzheimer's disease treatment | |
| IL248935A0 (en) | Diagnostic test and treatment/prevention of alzheimer's disease | |
| PL3137097T3 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| EP3773500A4 (en) | Compositions and methods of detecting and treating alzheimer's disease | |
| PL3137093T3 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| DK3137094T3 (en) | TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE (AD) | |
| SG11202101274XA (en) | Benzimidazole compounds and use thereof for treating alzheimer's disease or huntington's disease | |
| IL265656A (en) | Compositions and methods for treating alzheimer's disease and parkinson's disease |